Carbamazepine toxicity: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - " ==" to "==") |
Neil.m.young (talk | contribs) (Text replacement - "== " to "==") |
||
| Line 3: | Line 3: | ||
*Therapeutic concentration: 4-12 | *Therapeutic concentration: 4-12 | ||
== Clinical Features== | ==Clinical Features== | ||
*May be delayed and follow crescendo-decrescendo course (due to delayed GI motility) | *May be delayed and follow crescendo-decrescendo course (due to delayed GI motility) | ||
Revision as of 10:37, 5 July 2016
Background
- Has anticholinergic and antiepileptic effects
- Therapeutic concentration: 4-12
Clinical Features
- May be delayed and follow crescendo-decrescendo course (due to delayed GI motility)
- CNS
- Ataxia
- Nystagmus
- Coma
- Anticholinergic Toxicity
- CV
- Dysrhythmias are rare but may occur
- Wide QRS
- QT Prolongation
Diagnosis
- Levels do not accurately correlate w/ clinical severity
Treatment
- GI detox
- Activated Charcoal (if presents w/in 1hr of ingestion)
- Dialysis is effective (if needed)
Disposition
- Consider discharge for patient with decreasing levels (measured few hrs apart) and is asymptomatic